Pfizer Ngenla 60mg/1.2mL is a long acting growth hormone medication containing somatrogon, used to support growth in children with diagnosed growth hormone deficiency. Supplied in a convenient prefilled pen for once weekly dosing.
FormatPrefilled Pen
Concentration50mg/mL
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Ngenla, manufactured by Pfizer, contains Somatrogon, a long acting recombinant human growth hormone analogue with a fundamentally different molecular structure from standard rHGH preparations like Genotropin. Somatrogon is engineered through the fusion of the native growth hormone sequence with three copies of a carboxy terminal peptide (CTP) derived from human chorionic gonadotropin’s beta subunit. A structural modification specifically designed to extend the compound’s plasma half-life from the daily administration requirement of standard rHGH to a once weekly dosing schedule.
The CTP fusion technology underlying Somatrogon’s extended half-life represents a meaningfully different approach to growth hormone axis research compared to every other compound in CSD’s range. Standard rHGH formulations like Genotropin require daily or near daily administration due to native somatropin’s short plasma half-life. GHRH analogues and GHRPs stimulate endogenous pulsatile GH secretion through receptor mediated pathways rather than delivering exogenous hormone directly. Somatrogon delivers the growth hormone molecule itself, like standard rHGH but with CTP fusion extending its circulating half-life sufficiently to support once weekly administration, producing a sustained growth hormone exposure profile that differs from both the pulsatile pattern of endogenous secretion and the daily peaks of standard rHGH administration.
Pfizer’s pharmaceutical manufacturing of Ngenla carries full regulatory approval for pediatric growth hormone deficiency, contributing clinical trial data examining the pharmacokinetic and pharmacodynamic differences between once weekly Somatrogon and daily rHGH administration. Comparative research area unique to long acting GH analogues. As with Pfizer’s Genotropin, authenticity verification is a relevant consideration given counterfeit risk in the pharmaceutical branded growth hormone category, and CSD verifies genuine Pfizer product through its sourcing process before stocking. Within CSD’s growth hormone research range, Ngenla’s CTP fused extended half-life profile positions it as a distinct research subject from standard rHGH, GHRH analogues, and GHRPs.
Pfizer Ngenla is stocked by Canada Steroid Depot following the same rigorous third party verification process applied to every product in our range, with additional authenticity verification specific to pharmaceutical branded products. CSD’s sourcing standards ensure genuine Pfizer product reaches researchers requiring verified pharmaceutical grade long acting growth hormone analogues. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Intended for research purposes only.
Commonly researched alongside standard rHGH and GHRH analogue compounds in comparative growth hormone axis activation pattern studies. Browse CSD’s full HGH and peptide range for complete sourcing.
NGENLA is Pfizer's long acting human growth hormone analog containing somatrogon ghla. The 60mg prefilled pen contains 1.2mL of solution at a concentration of 50mg/mL. It is supplied as a prefilled, premixed multidose pen and does not require reconstitution.
In the United States, NGENLA is approved for the treatment of pediatric patients aged 3 years and older who have growth failure caused by inadequate secretion of endogenous growth hormone. It is a prescription medication intended to be managed by a healthcare professional experienced in pediatric growth hormone deficiency.
Somatropin is recombinant human growth hormone with the same 191 amino acid sequence as endogenous growth hormone. Somatrogon ghla contains the human growth hormone sequence fused with three C-terminal peptide regions derived from the beta chain of human chorionic gonadotropin. This modification extends its activity and allows NGENLA to be administered on a once weekly schedule rather than the daily schedule used by many somatropin products.
Somatrogon ghla binds to growth hormone receptors and activates downstream signaling pathways, including STAT5b. This increases insulin like growth factor 1 (IGF-1) concentrations and produces growth hormone related effects on linear growth and metabolism. Its estimated effective half-life is approximately 37.7 hours in pediatric patients with growth hormone deficiency.
No. NGENLA is supplied as a sterile, prefilled and premixed solution in a disposable multidose pen. The 60mg pen contains 1.2mL of solution and delivers doses in 0.5mg increments. Before and after first use it should be refrigerated at 2–8°C, and after first use the pen may be kept refrigerated for up to 28 days.
![PFIZER NGENLA 60MG/1.2ML [GROWTH HORMONE]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/07/ngenla-600x600.webp)
![PFIZER NGENLA 60MG/1.2ML [GROWTH HORMONE]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/07/ngenla-100x100.webp)